Synergistic Use of Geniposide and Ginsenoside Rg1 Balance Microglial TNF- and TGF-1 following Oxygen-Glucose Deprivation In Vitro: A Genome-Wide Survey

Figure 3

Venn diagrams show comparative analysis of gene expression profiles among geniposide-, ginsenoside-Rg1-, and the combination-treated groups. (a) Upregulated differentially expressed genes overlapping and nonoverlapping among the 3 treatment groups. (b) Downregulated differentially expressed genes overlapping and nonoverlapping among the 3 treatment groups. (c) Real-time qRT-PCR validation of the DGE results. DGE results compared to qRT-PCR results relative to the Ct value. The most clearly upregulated or downregulated genes in the 3 treatment groups from DGE data (FDR ; fold change >1.5) were selected. β-actin was used as a normalizer for each experiment. Expression changes are depicted as log-2-fold change (-axis). Gene symbols are shown on the other side of the column. (d) USP17L protein expression in model group and geniposide-treatment group determined by western blotting. (e) Fcrlb protein expression in model group and combination-treated group determined by western blotting. M versus G-up (down), up- (down-) regulated genes in geniposide-treated group compared with model group; M versus R-up (down), up- (down-) regulated genes in ginsenoside-Rg1-treated group compared with model group; M versus G+R-up (down), up- (down-) regulated genes in combination-treated group compared with model group. G versus M, differential expressed genes in geniposide-treated group compared with model group; R versus M, differential expressed genes in ginsenoside-Rg1-treated group compared with model group; G+R versus M, differential expressed genes in combination-treated group compared with model group.

(a)

(b)

(c)

(d)

(e)